文献速递心境障碍

鞘脂在重性抑郁障碍及相关认知损害中的作用

The role of sphingolipids in major depressive disorder and associated cognitive impairment: interactions with monoaminergic signaling, neuroinflammation, and neurogenesis.
PubMed 文献 · Mol Psychiatry · 2026-05-13

本文综述鞘脂(神经酰胺、鞘磷脂及其代谢物)在重性抑郁障碍(MDD)病理生理及认知损害中的作用,聚焦其与单胺能信号、神经炎症、神经发生、线粒体功能障碍、谷氨酸信号及突触可塑性的交互。临床研究显示MDD患者鞘脂谱改变,神经酰胺水平升高与抑郁严重度相关;临床前证据支持鞘脂改变与抑郁行为存在潜在因果关联。多种抗抑郁药通过抑制酸性鞘磷脂酶(ASM)或间接调节该通路影响鞘脂代谢,提示鞘脂失调可能是MDD多条病理通路汇聚的中心节点。

要点

  • MDD患者存在鞘脂谱改变,神经酰胺升高与抑郁严重度相关。
  • 鞘脂失调与单胺能信号、神经炎症、神经发生等通路交互。
  • 多种抗抑郁药通过抑制ASM或调节鞘脂代谢发挥作用。

核心结论

  • 鞘脂失调可能是MDD多条病理生理通路汇聚的中心节点,并可能解释其生物学异质性及常见认知损害。

研究设计与样本

  • 综述,总结临床研究、临床前证据及抗抑郁药对鞘脂代谢的作用机制。

主要发现

  • 临床研究显示MDD患者鞘脂谱改变,神经酰胺水平升高与抑郁严重度相关。
  • 临床前证据支持鞘脂改变通过影响神经传递、神经可塑性、神经发生、线粒体功能及炎症过程与抑郁行为存在潜在因果关联。
  • 多种已确立的抗抑郁药通过直接作为ASM功能抑制剂或间接调节该通路影响鞘脂代谢。

关键数值与推荐

  • 约三分之一MDD患者对常规治疗抵抗。
  • 鞘脂包括神经酰胺、鞘磷脂及其代谢物。

临床怎么用

  • 鞘脂代谢可能为MDD认知损害提供机制解释,并支持通过生物标志物开发和鞘脂靶向治疗推进个性化医疗。

局限性

  • 本文为综述,未报告原始研究的具体样本量、效应量或置信区间等数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Major depressive disorder (MDD) represents a leading cause of disability. Despite decades of research focused on monoaminergic dysregulation, the exact pathophysiological mechanisms underlying MDD remain incompletely understood. This gap in knowledge has contributed to suboptimal therapeutic outcomes, with approximately one-third of MDD patients showing resistance to conventional treatments. Recent advances in lipidomics support that sphingolipids-including ceramides, sphingomyelins, and their metabolites-could play important roles in depression pathophysiology. This review examines the role of sphingolipid dysregulation in MDD and associated cognitive impairment, with a particular focus on interactions with neurogenesis and apoptosis, monoaminergic signaling, neuroinflammation, mitochondrial dysfunction and oxidative stress, glutamatergic signaling, and synaptic plasticity. Several clinical studies demonstrate altered sphingolipid profiles in MDD patients, with elevated ceramide levels correlating with depression severity. Preclinical evidence supports potential causal relationships between sphingolipid alterations and depressive behaviors through effects on neurotransmission, neuroplasticity, neurogenesis, mitochondrial function, and inflammatory processes. Many established antidepressants influence sphingolipid metabolism through distinct mechanisms-acting directly as functional inhibitors of acid sphingomyelinase (ASM) or modulating this pathway indirectly. This mechanistic convergence positions sphingolipid dysregulation as a potential central mediating node across major pathophysiological pathways in MDD and as a common pathway through which key risk factors may converge, potentially explaining its biological heterogeneity. Sphingolipid metabolism also offers a potential mechanistic explanation for the frequently observed cognitive deficits in MDD. This review synthesizes current evidence regarding sphingolipid involvement in depression pathophysiology and outlines promising avenues for personalized medicine through biomarker development and sphingolipid-targeted therapeutics.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Hoertel N, Mühle C, Müller CP, et al. The role of sphingolipids in major depressive disorder and associated cognitive impairment: interactions with monoaminergic signaling, neuroinflammation, and neurogenesis. Mol Psychiatry. 2026. PMID: 42129477. doi:10.1038/s41380-026-03649-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。